Amporin Pharmaceuticals

We are developing a new class of small molecule drugs as the first acute oral disease-modifying treatments for at least 6 deadly chronic degenerative diseases, including Parkinsons disease and ALS.

We have already demonstrated Proof of Concept, with acute oral disease reversal in vivo: A single oral dose of our prototype drug candidate was shown to fully restore cognitive and motor function in two established animal models of Alzheimer’s and Parkinson’s disease, with no adverse effects in normal healthy animals. This has never been seen before.

At least 50 deadly chronic degenerative diseases, including Alzheimer’s, Parkinson’s, type II diabetes, and many rare degenerative diseases, are now associated with protein misfolding and aggregation. Together, these diseases affect over half a billion people and kill 3.6 million people around the world each year, at a total cost to society of USD 3 trillion per year. Moreover, these diseases are growing rapidly with the ageing population, and yet there are still no effective treatments that can stop or reverse the underlying process of degeneration.

We are developing 3 breakthrough new classes of small molecule drugs which have been specifically designed to block, dissolve and degrade the toxic soluble oligomers and pores formed by any disease-associated protein or peptide within cell membranes, as the first acute oral disease-modifying treatments for multiple degenerative diseases.

We plan to develop and license out at least 6 drug candidates to big pharma companies after demonstrating their superior safety and efficacy in Phase 2 trials, or even earlier in Phase 1b trials. Pharma companies are especially desperate to fill their pipelines with potential treatments for these diseases, as shown by several recent multi-billion dollar deals in this space.

3rd place winner of Swiss Venture business plan competition.
Winner of Venture Kick Stage III support for Swiss Startups.
Recipient of InnoSuisse initial and core startup coaching grants.